WHANIN PHARM CO.,LTD Logo

WHANIN PHARM CO.,LTD

Develops and sells pharmaceuticals, specializing in CNS, cardiovascular, and GI drugs.

016580 | KO

Overview

Corporate Details

ISIN(s):
KR7016580003
LEI:
Country:
South Korea
Address:
서울특별시 송파구 법원로6길 11 (문정동, 환인빌딩), 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Whanin Pharm Co., Ltd. is a pharmaceutical company focused on the development, manufacturing, and sale of therapeutic products. The company specializes in medications for the Central Nervous System (CNS), offering a range of neuropsychiatric drugs including anti-depressants, anti-psychotics, and nootropics. In addition to its core CNS portfolio, Whanin Pharm also produces pharmaceuticals for other therapeutic categories such as cardiovascular and gastrointestinal treatments, as well as antibiotics. The company actively engages in research and development to create innovative medications, extending its focus beyond CNS to the broader healthcare sphere.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-13 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 1.7 MB
2025-08-13 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.4 MB
2025-08-01 00:00
Earnings Release
연결재무제표기준영업(잠정)실적(공정공시)
Korean 15.9 KB
2025-07-11 00:00
Transaction in Own Shares
자기주식처분결과보고서
Korean 19.7 KB
2025-07-07 00:00
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
Korean 30.6 KB
2025-05-14 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.3 MB
2025-04-30 00:00
Earnings Release
연결재무제표기준영업(잠정)실적(공정공시)
Korean 15.9 KB
2025-03-21 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 9.8 KB
2025-03-21 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 24.9 KB
2025-03-13 00:00
Audit Report / Information
감사보고서제출
Korean 20.1 KB
2025-03-13 00:00
Annual Report
사업보고서 (2024.12)
Korean 1.8 MB
2025-03-05 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 830.1 KB
2025-03-05 00:00
Pre-Annual General Meeting Information
주주총회집중일개최사유신고
Korean 4.9 KB
2025-02-28 00:00
Notice of Dividend Amount
현금ㆍ현물배당결정
Korean 8.4 KB
2025-02-28 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 13.7 KB

Automate Your Workflow. Get a real-time feed of all WHANIN PHARM CO.,LTD filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for WHANIN PHARM CO.,LTD

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for WHANIN PHARM CO.,LTD via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Solid Biosciences Inc. Logo
Advancing gene therapies and technologies for rare neuromuscular and cardiac diseases.
United States of America
SLDB
SOLIGENIX, INC. Logo
Late-stage biopharma developing treatments for rare diseases and public health threats.
United States of America
SNGX
Sonnet BioTherapeutics Holdings, Inc. Logo
Develops targeted cytokine therapies for cancer using a proprietary albumin-binding platform.
United States of America
SONN
Sonoma Pharmaceuticals, Inc. Logo
Develops and sells stabilized HOCl products for wound, skin, eye, nasal, and animal healthcare.
United States of America
SNOA
Sopharma AD Logo
Develops, manufactures, and distributes pharmaceuticals and generics in Bulgaria and regional markets.
Bulgaria
SFA
Spago Nanomedical AB Logo
Developing nanomedicines for precise cancer diagnosis and targeted radionuclide therapy.
Sweden
SPAGO
Spero Therapeutics, Inc. Logo
Develops novel treatments for multi-drug resistant bacterial infections and rare diseases.
United States of America
SPRO
Spexis AG Logo
Clinical-stage biopharma developing macrocyclic therapeutics for rare diseases and oncology.
Switzerland
SPEX
Sprint Bioscience Logo
Develops & out-licenses preclinical oncology drugs for difficult-to-treat cancers.
Sweden
SPRINT
SPRUCE BIOSCIENCES, INC. Logo
Developing first-in-class therapies for serious, underserved neurological conditions like MPS IIIB.
United States of America
SPRB

Talk to a Data Expert

Have a question? We'll get back to you promptly.